Systemic RNAi Delivery Gets Traction as Four Shops Prep for Phase I; Others Report Delays | GenomeWeb
Although it has been two and a half years since the first siRNA-based therapeutic entered clinical trials, that and other candidates that have reached human testing have all been directly delivered.
 
That is set to change this summer. After a bumpy start, Nucleonics now expects to start a phase I study of its systemically delivered hepatitis B treatment NucB 1000.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.